General Information and Variability Data of DT
DT ID DTD0030
Gene Name SLCO1B3
Protein Name Organic anion transporting polypeptide 1B3
Synonyms LST-2; LST-3TM13; LST2; LST3; Liver-specific organic anion transporter 2; OATP-8; OATP1B3; OATP8; Organic anion transporter 8; Organic anion-transporting polypeptide 8; SLC21A8; SLCO1B3; Solute carrier family 21 member 8; Solute carrier organic anion transporter family member 1B3
Gene ID
28234
UniProt ID
Q9NPD5
TCDB ID
2.A.60.1.12
DT Family Organo Anion Transporter (OAT) Family ;
Tissue Specificity Highly expressed in liver, in particular atthe basolateral membrane of hepatocytes near the central vein. Notdetected in other tissues. Highly expressed in some cancer celllines derived from colon, pancreas, liver and gall bladder.
Function This transporter involved in the clearance of bile acids and organic anions from the liver. Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP).
Disease(s) Breast cancer [ICD-11: 2C60-2C6Z]
Diabetes [ICD-11: 5A10-5A14]
Dyslipidaemias [ICD-11: 5C8Z]
Heart failure [ICD-11: BD1Z]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Osteoporosis [ICD-11: FB83.1]
Pemphigus vulgaris [ICD-11: EB40.0]
Urinary tract and skin bacteria infections [ICD-11: GC08]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Atorvastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [1]
Bosentan Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [2]
Cefmetazole Drug Info Urinary tract and skin bacteria infections [ICD-11: GC08] Approved [3]
Cefoperazone Drug Info Pseudomonas bacterial infections [ICD-11: 1B92] Approved [3]
Ceftriaxone Drug Info Pneumonia [ICD-11: CA40] Approved [3]
Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [1]
Cilostazol Drug Info Intermittent claudication [ICD-11: BD40.00] Approved [4]
Crizotinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [5]
Dasatinib Drug Info Multiple myeloma [ICD-11: 2A83] Approved [5]
Dehydroepiandrosterone sulfate Drug Info Dyspareunia [ICD-11: GA12] Approved [6]
Diclofenac Drug Info Osteoarthritis of knee [ICD-11: FA01] Approved [7]
Digoxin Drug Info Arrhythmias [ICD-11: BC60-BC9Z] Approved [8]
Docetaxel Drug Info Lung cancer [ICD-11: 2C25] Approved [9]
Enalapril Drug Info High blood pressure [ICD-11: BA00] Approved [10]
Erythromycin Drug Info Pelvic inflammatory disease [ICD-11: GA05] Approved [11]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [12]
Etoposide Drug Info Testicular cancer [ICD-11: 2C80] Approved [12]
Fexofenadine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [13]
Fluorescein Drug Info Ocular disease [ICD-11: 9E1Z] Approved [14]
Fluvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [15]
Gadobenate dimeglumine Drug Info CNS imaging [ICD-11: XD47Y1] Approved [16]
Gefitinib Drug Info Urethral cancer [ICD-11: 2F78] Approved [5]
Glutathione Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [17]
Hydroxyurea Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [18]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [5]
Indocyanine green Drug Info Gastrointestinal disease [ICD-11: DE2Z] Approved [19]
Liothyronine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [6]
Mesalazine Drug Info Recurrent ventricular fibrillation [ICD-11: BC71.1] Approved [20]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [6]
Mycophenolate mofetil Drug Info Pemphigus vulgaris [ICD-11: EB40.0] Approved [21]
Nateglinide Drug Info Diabetes [ICD-11: 5A10-5A14] Approved [1]
Nilotinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [5]
Olmesartan medoxomil Drug Info High blood pressure [ICD-11: BA00] Approved [22]
Ouabain Drug Info Heart failure [ICD-11: BD1Z] Approved [8]
Paclitaxel Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [23]
Pitavastatin Drug Info Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] Approved [11]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [24]
Pravastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [25]
Rifampicin Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [26]
Romidepsin Drug Info Cutaneous T-cell lymphoma [ICD-11: 2B0Z] Approved [27]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [28]
Sorafenib Drug Info Pancreatic cancer [ICD-11: 2C10] Approved [5]
Sunitinib Drug Info Imatinib-resistant gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [5]
Technetium (99MTC) mebrofenin Drug Info Imaging of liver and gallbladder [ICD-11: XD47Y1] Approved [29]
Telmisartan Drug Info High blood pressure [ICD-11: BA00] Approved [30]
Testosterone Drug Info Osteoporosis [ICD-11: FB83.1] Approved [31]
Valsartan Drug Info High blood pressure [ICD-11: BA00] Approved [32]
Vandetanib Drug Info Thyroid gland tumours [ICD-11: 2D10] Approved [5]
Vemurafenib Drug Info Thyroid cancer [ICD-11: 2D10] Approved [5]
Warfarin Drug Info Atrial fibrillation [ICD-11: BC81.3] Approved [2]
Clinical Trial Drug(s) Transported by This DT Benzylpenicillin Drug Info Gram-positive bacteria infections [ICD-11: 1A00-1H0Z] Phase 4 [33]
Primovist Drug Info Lung cancer [ICD-11: 2C25] Phase 4 [34]
Atrasentan Drug Info Endothelial dysfunction [ICD-11: BE2Z] Phase 3 [35]
Glycocholic acid Drug Info Bile acid synthesis defect [ICD-11: 5C52.11] Phase 3 [8]
BQ-123 Drug Info ST-Elevation myocardial infarction [ICD-11: BA41.0] Phase 2 [8]
Danoprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 2 [1]
SN-38 Drug Info Colon cancer [ICD-11: 2B90.Z] Phase 2 [9]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Sodium taurocholate Drug Info Type 2 diabetes [ICD-11: 5A11] Preclinical [6]
Sincalide Drug Info Discovery agent [ICD-11: N.A.] Preclinical [36]
Taurocholic acid Drug Info Type 2 diabetes [ICD-11: 5A11] Terminated [12]
Endogenous Substrate(s) Cholate; Cholecystokinin; 17Beta-glucuronosyl estradiol; Cholecystokinin 8; Monoglucuronosyl bilirubin; Tauroursodeoxycholate
Endogenous Metabolites (EMs) Handled by This DT Bile salt unspecific EM Info Unclear experiment used for identifying this EM [37]
Hormone metabolite unspecific EM Info Unclear experiment used for identifying this EM [37]
Thyroxine EM Info Unclear experiment used for identifying this EM [37]
Triiodothyronine EM Info Unclear experiment used for identifying this EM [37]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Amanitin Drug Info Madin-Darby canine kidney cells (MDCKII)-OATP1B3 Km = 3.7 microM [33]
Atorvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.73 microM [36]
Bilirubin Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.5 microM [38]
Bilirubin Drug Info Oocytes-OATP1B3 Km = 0.0391 microM [39]
Bosentan Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 141 microM [2]
Bromsulphthalein Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.3 microM [38]
Bromsulphthalein Drug Info Oocytes-OATP1B3 Km = 0.4 microM [8]
Cilostazol Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 2.7 microM [4]
Estradiol-17beta-glucuronide Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 15.8 microM [12]
Estradiol-17beta-glucuronide Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 24.6 microM [24]
Estrone sulfate Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 58 microM [12]
Fexofenadine Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 108 microM [13]
Fluo-3 Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 3.1 microM [12]
Fluvastatin Drug Info Madin-Darby canine kidney cells (MDCKII)-OATP1B3 Km = 7 microM [40]
Liothyronine Drug Info Oocytes-OATP1B3 Km = 6.4 microM [6]
Mesalazine Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 77.4 microM [20]
Methotrexate Drug Info Madin-Darby canine kidney (MDCK) cells-OATP1B3 Km = 39.4 microM [6]
Methotrexate Drug Info Oocytes-OATP1B3 Km = 24.7 microM [6]
Olmesartan medoxomil Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 44.2 microM [22]
Olmesartan medoxomil Drug Info Oocytes-OATP1B3 Km = 71.8 microM [41]
Paclitaxel Drug Info Oocytes-OATP1B3 Km = 6.79 microM [23]
Pitavastatin calcium Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.25 microM [24]
Pitavastatin calcium Drug Info Oocytes-OATP1B3 Km = 3.8 microM [42]
Rifampicin Drug Info Oocytes-OATP1B3 Km = 2.3 microM [26]
Rosuvastatin Drug Info Human cervical cancer cell line (Hela)-OATP1B3 Km = 9.8 microM [43]
Rosuvastatin Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 14.2 microM [28]
Sincalide Drug Info Oocytes-OATP1B3 Km = 11.1 microM [44]
Sodium taurocholate Drug Info Oocytes-OATP1B3 Km = 5.8 microM [6]
Telmisartan Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 0.81 microM [30]
Telmisartan Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 3.4 microM [45]
Valsartan Drug Info Chinese hamster ovary (CHO) cells-OATP1B3 Km = 23.5 microM [46]
Valsartan Drug Info Human embryonic kidney cells (HEK293)-OATP1B3 Km = 18.2 microM [32]
References
1 FDA Drug Development and Drug Interactions
2 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
3 Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
4 Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
5 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
6 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
7 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
8 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
9 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
10 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
11 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
12 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
13 Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
14 Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.
15 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
16 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
17 Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
18 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
19 Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.
20 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
21 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
22 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
23 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
24 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
25 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
26 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
27 Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
28 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
29 Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45.
30 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
31 Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8.
32 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
33 Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
34 Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010 Jul;38(7):1024-8.
35 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
36 Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63.
37 Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1). Biochim Biophys Acta. 2016 Nov;1858(11):2894-2902.
38 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30.
39 Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J. 2003 May 1;371(Pt 3):897-905.
40 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
41 OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
42 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
43 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
44 Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology. 2001 Nov;121(5):1185-90.
45 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
46 Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.